EE359 US Cost-Effectiveness of Chimeric Antigen Receptor T-Cell (CAR T) Therapy for Patients with Relapsed or Refractory Large B-Cell Lymphoma (R/R LBCL), Considering Infusion Setting and Payor Claims Data
Jul 1, 2022, 00:00
10.1016/j.jval.2022.04.607
https://www.valueinhealthjournal.com/article/S1098-3015(22)00808-7/fulltext
Title :
EE359 US Cost-Effectiveness of Chimeric Antigen Receptor T-Cell (CAR T) Therapy for Patients with Relapsed or Refractory Large B-Cell Lymphoma (R/R LBCL), Considering Infusion Setting and Payor Claims Data
Citation :
https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(22)00808-7&doi=10.1016/j.jval.2022.04.607
First page :
Section Title :
Open access? :
No
Section Order :
10543